50th week of 2012 patent applcation highlights part 45 |
Patent application number | Title | Published |
20120316157 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more heterocyclic fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of fenamidone, acibenzolar-S-methyl, amisulbrom, anilazine, dazomet, diclomezine, diflumetorin, famoxadone, fenoxanil, ferimzone, nuarimol, piperalin, probenazole, proquinazid, pyrifenox, pyroquilon, quinoxyfen, tricyclazole, isoprothiolane, tiadinil, and oxolinic acid | 2012-12-13 |
20120316158 | OPHTHALMIC SOLUTION FOR TREATING OCULAR INFECTION COMPRISING LEVOFLOXACIN OR SALT THEREOF OR SOLVATE OF THE SAME, METHOD FOR TREATING OCULAR INFECTION, LEVOFLOXACIN OR SALT THEREOF OR SOLVATE OF THE SAME, AND USE THEREOF - Instillation of a 1.5% (w/v) levofloxacin ophthalmic solution three times a day, which is the dosage or dose regimen of the present invention, has features to cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w/v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infection-causing bacterium to levofloxacin. Therefore, the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention is eventually expected to suppress emergence of the resistant bacterium resulting from the long-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen. In addition, it is confirmed that the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention directly inhibits the ocular-infection-causing bacterium such as | 2012-12-13 |
20120316159 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS - This invention relates to bicyclic ring system substituted sulfonamide functionalized phenols of general formula 1, | 2012-12-13 |
20120316160 | XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLA- MINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE - The present invention relates to the xinafoate salt of N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine. This compound is a suitable drug substance and is useful in the treatment of conditions including asthma. | 2012-12-13 |
20120316161 | NOVEL ANTIVIRAL COMPOUNDS - The present invention relates to compounds of formula (A) as defined herein having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having antiviral activity. | 2012-12-13 |
20120316162 | PIPERIDINE AND PIPERAZINE DERIVATIVES - Compounds of the formula (I), in which R | 2012-12-13 |
20120316163 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors - The present invention is related to pyrazolo piperidine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). | 2012-12-13 |
20120316164 | METHOD FOR INHIBITING THE GROWTH OF CANCER STEM CELLS - The present invention provides a method for inhibiting the growth of cancer stem cells, particularly colorectal cancer stem cells, liver cancer stem cells, lung cancer stem cells or breast cancer stem cells, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of antimycin A or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier. | 2012-12-13 |
20120316165 | SUBSTITUTED BENZAMIDE DERIVATIVES - The present invention relates to compounds of formula | 2012-12-13 |
20120316166 | HETARYLAMINONAPHTHYRIDINES - Novel hetarylaminonaphthyridine derivatives of formula (I) | 2012-12-13 |
20120316167 | SECONDARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES - The present invention provides new secondary 8-hydroxyquinoline-7-carboxamide derivatives of general formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful as antifungal agents. Specifically, these compounds were tested against | 2012-12-13 |
20120316168 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides a quinolone compound represented by General Formula (1) | 2012-12-13 |
20120316169 | 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - (R,S) 2-aryl-propionamide derivatives, or their single enantiomers (R) and (S) are disclosed useful in the treatment or prevention of symptoms and disorders such as pain and inflammation associated with the bradykinin B1 pathway. | 2012-12-13 |
20120316170 | Imidazole Derivative - To provide a novel compound or an isotope thereof or a pharmaceutically acceptable salt thereof having S1P lyase inhibitory capacity and inducing the decrease in number of lymphocytes, and a pharmaceutical composition containing these as active ingredients. A compound represented by the general formula (I): | 2012-12-13 |
20120316171 | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer - Methods and compositions for the treatment and/or management of cancer are disclosed, which comprise the use of tryptophan hydroxylase inhibitors. | 2012-12-13 |
20120316172 | PYRAZOLE DERIVATIVES - The invention relates to compounds of formula IA and IB | 2012-12-13 |
20120316173 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR - Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 2012-12-13 |
20120316174 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS - The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. | 2012-12-13 |
20120316175 | SOLID STATE FORMS OF SITAGLIPTIN SALTS - Solid state forms of Sitagliptin salts, processes for preparing the solid state forms, and pharmaceutical compositions thereof, are provided. | 2012-12-13 |
20120316176 | DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF - The present invention relates to derivatives of 7,8-dihydro-1H-imidazo[2,1-b]purin-4(5H)-one, compositions thereof and methods of use thereof for treating or preventing pain or an inflammatory disease. | 2012-12-13 |
20120316177 | EXTENDED RELEASE PREPARATION - Disclosed is a sustained release preparation which releases a poorly soluble medicinal agent in a pH-independent manner. Also disclosed is a sustained release preparation which is capable of controlling the C | 2012-12-13 |
20120316178 | PIPERAZINES AS ANTIMALARIAL AGENTS - The invention relates to novel piperazine derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria. | 2012-12-13 |
20120316179 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF - The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period. | 2012-12-13 |
20120316180 | LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF - The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous Aripiprazole crystals is stored for an extended period. | 2012-12-13 |
20120316181 | HEXAHYDRO-1H-4,7-METHANOISOINDOLE-1,3-DIONE COMPOUNDS - The present invention is directed to therapeutic agents which are atypical antipsychotics and which are useful in the treatment of neurological and psychiatric disorders associated with dopamine D2 and serotonin 5-HT2A neurotransmission dysfunction. | 2012-12-13 |
20120316182 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2012-12-13 |
20120316183 | NOVEL SOLVATES OF METHYLCARBAMATE - The invention relates to novel solvates of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate, in particular the semi-ethanol solvate of the formula (Ia), to processes for their preparation, to medicaments comprising them and to their use for controlling diseases | 2012-12-13 |
20120316184 | NOVEL MICROBICIDES - Compounds of formula (I) wherein G | 2012-12-13 |
20120316185 | Cyclohexyl Amide Derivatives as CRF Receptor Antagonists - There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF) receptor antagonists Formula (I). | 2012-12-13 |
20120316186 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2012-12-13 |
20120316187 | MOLECULAR BIOMARKERS FOR PREDICTING RESPONSE TO TYROSINE KINASE INHIBITORS IN LUNG CANCER - The invention relates to a method for predicting the response to the treatment with an EGFR tyrosine kinase inhibitor of a patient suffering lung cancer an carrying a mutation in the EGFR gene based on the expression levels in a sample of said patient of the BRCA1 gene wherein low BRCA1 expression levels are indicative of a positive response of a patient. This positive response is also observed in patients showing the T790M mutation in the EGFR gene which is usually associated with resistance to EGFR tyrosine kinase inhibitors. | 2012-12-13 |
20120316188 | PREPARATION OF 4-AMINO-THIAZOLES AND 3-AMINO-1,2,4-THIADIAZOLES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds of Formula (I), wherein M, P, X, A and (B) | 2012-12-13 |
20120316190 | Modulation of Cell Barrier Dysfunction - The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist, e.g., N-methylnaltrexone or a salt thereof, to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders, e.g., inflammatory bowel disease. Methods of reducing the symptoms of inflammatory bowel disease and the risk of developing inflammatory bowel disease are also provided. | 2012-12-13 |
20120316192 | SUBSTITUTED INDOLO [2,3-A] QUINOLIZINES - The present invention relates to novel substituted indolo[2,3-a]quinolizines and stereoisomeric forms thereof and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted indolo[2,3-a]quinolizines together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted indolo[2,3-a]quinolizines have been identified as useful for the prophylaxis and treatment of cancer by the induction of strong mitotic delays, chromosomal misalignments and mitotic tri- and multipolarization leading to cell cycle stop and apoptosis. Furthermore a synthesis for preparation of the substituted indolo[2,3-a]quinolizines is disclosed in the present invention. | 2012-12-13 |
20120316193 | PROTEOSTASIS REGULATORS - The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds. | 2012-12-13 |
20120316194 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS - The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula | 2012-12-13 |
20120316195 | ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R | 2012-12-13 |
20120316196 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine - Compounds of formula (I) or a salt thereof are provided: | 2012-12-13 |
20120316197 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES - This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a pharmaceutical composition for the treatment of immune disease or allergy which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of immune disease or allergy in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. | 2012-12-13 |
20120316198 | HYDRAZONE AND DIACYL HYDRAZINE COMPOUNDS AND METHODS OF USE - Disclosed herein are novel hydrazone and diacyl hydrazine derivatives that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Also disclosed are hydrazone and diacyl hydrazine derivatives as potent and selective inhibitors of the p97 ATPase. These agents provide useful tools for the study of protein degradation and other processes involving p97. Methods of treating diseases or disorders for which p97 inhibition and/or ER stress induction is an effective treatment with certain hydrazone and diacyl hydrazine derivatives are also disclosed. | 2012-12-13 |
20120316199 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN - A composition for treating, controlling, reducing, or ameliorating inflammatory pain comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It may be used in a method of managing post-surgical ocular pain such that it has lower risk of eliciting adverse side effects seen with other therapeutic agents. | 2012-12-13 |
20120316200 | PYRIDONE DERIVATIVES - The present invention is directed to novel phenylpyridone derivative compounds. The compounds act as a melanin concentrating hormone receptor antagonists, and can be useful in preventing, treating or acting as a remedial agent for various circular system diseases, nervous system diseases, metabolic diseases, genital diseases, respiratory diseases and digestive diseases. | 2012-12-13 |
20120316201 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT - The invention relates to novel benzimidazole and imidazopyridine derivatives having the general Formula (I), which have a good affinity with certain subtypes of melanocortin receptors, particularly MC4 receptors. The derivatives are particularly suitable for the treatment of pathological states and diseases involving one or more melanocortin receptors. The invention also relates to pharmaceutical compositions containing said the compounds having the general Formula (I). | 2012-12-13 |
20120316202 | Compounds which have activity at M1 receptor and their uses in medicine - Compounds of the general formula | 2012-12-13 |
20120316203 | Compositions and Methods for Inhibition of Cancers - Methods and compositions for treating cancers, including ovarian cancers, are described. The compositions generally include a redox based curcumin derivative, diarylidenylpiperiden-4-one (DAP) having a hydroxylamine moiety attached thereto. | 2012-12-13 |
20120316204 | COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER - Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible factor-2 alpha (HIF-2α) and thereby provide a method for treating cancer. Further disclosed are compositions which comprise {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and/or a prodrug thereof which can be used to treat cancer. | 2012-12-13 |
20120316205 | OIL DISPERSION OF SULFOXIMINES FOR THE CONTROL OF INSECTS - The invention relates to oil dispersions of sulfoximine insecticides, such as sulfoxaflor, and methods of using these dispersions to control insects such as whitefly. | 2012-12-13 |
20120316206 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more carbamate fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of benthiavalicarb, iprovalicarb, propamocarb, and metam | 2012-12-13 |
20120316207 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 2012-12-13 |
20120316208 | INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE THWART MYCOBACTERIAL GROWTH - Compounds which inhibit microbial growth or attenuate the virulence of pathogen microorganisms. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity as inhibitors of microbial growth of microorganisms which contain this enzyme and particularly those microorganisms in which this enzyme is responsible for the incorporation of galactofuranose residues, particularly for uridine 5′-diphosphate (UDP) galactopyranose mutase. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity to attenuate virulence of pathogenic microorganisms, including mycobacteria. | 2012-12-13 |
20120316209 | DIAGNOSTIC ASSAY FOR TRYPANOSOMA CRUZI INFECTION - A sensitive, multicomponent diagnostic test for infection with | 2012-12-13 |
20120316210 | TOPICAL ANTIPARASITIC FORMULATIONS - This invention recites topical formulations comprising demiditraz, fipronil, an acid modifier, at least one veterinarily acceptable carrier, and optionally, at least one antioxidant for treating a parasitic infection or infestation in animals. | 2012-12-13 |
20120316211 | Diagnostic Methods for Assessing Risk of Chagas Disease and Heart Failure - Provided herein are methods of detecting evidence of Chagas disease in a biological sample, comprising the step of measuring the presence of at least one protein selected from the group consisting of gelsolin, myosin light chain 2, vimentin, myosin heavy chain 11, vinculin, and plasminogen in said sample, wherein significantly elevated levels of the protein is a biomarker for the presence or severity of Chagas disease. | 2012-12-13 |
20120316212 | AMINO ALCOHOL DERIVATIVES AND THEIR THERAPEUTIC ACTIVITIES - The present invention relates to amino alcohol derivatives of general formula I: | 2012-12-13 |
20120316213 | COMBINATION OF ALPHA-2 RECEPTOR AGONIST (CLONIDIN) AND ANTI-MUSCARINIC AGENT (OXYBUTYNIN) FOR THE TREATMENT OF SIALORRHOEA - An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium. | 2012-12-13 |
20120316214 | SYNTHESIS PROCESS, AND CRYSTALLINE FORM OF 4-BENZAMIDE HYDROCHLORIDE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - Industrial synthesis process for, and crystalline form I of, the compound of formula (I): | 2012-12-13 |
20120316215 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS - Disclosed are methods for treating a subject suffering from phenylketonuria and/or phenylalanemia. The methods include, in part, enterally administering to the subject a LNAA supplement in which the weight ratio of Leu to Val is greater than 2:1; in which the weight ratio of Leu to iLeu is greater than 3:1; or which includes one or more LNAAs and which further includes Lys. LNAA supplements are also disclosed. Also disclosed are methods for treating a subject suffering from a condition involving a metabolic disorder involving the metabolism of a first amino acid X. The method includes enterally administering to the subject a composition which (i) is substantially free from the first amino acid X and (ii) which includes a second amino acid Y that competes with amino acid X at a gastrointestinal tract transporter. | 2012-12-13 |
20120316216 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention relates to the use of a compound of formula 1, | 2012-12-13 |
20120316217 | COMBINATION FOR THE TREATMENT OF OSTEOARTHRITIS - The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic viscosity-controlling polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of osteoarthritis. | 2012-12-13 |
20120316218 | SMALL NON-CODING REGULARTORY RNA's and METHODS FOR THEIR USE - Disclosed are methods and compositions related to small, non-coding RNA molecules having gene regulatory activity, compositions comprising same, and methods for their use. Provided are isolated small non-coding RNA molecules transcribed from an intergenic region of the human genome, wherein the intergenic region contains at least one small nucleotide polymorphism (SNP) associated with one or more human diseases or disorders. Also disclosed are methods for the detection of these small non-coding RNA molecules in a biological sample and related therapeutic, diagnostic, and prognostic methods. | 2012-12-13 |
20120316219 | MODULATION OF APOLIPOPROTEIN(A) EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided. | 2012-12-13 |
20120316220 | METHODS AND COMPOSITIONS FOR TREATING INSECTS - Provided herein are methods and compositions for modulating gene expression in insects by administering a composition comprising an RNA effector molecule and a delivery agent. Methods are provided for controlling pest populations by inhibiting insect growth, development, survival, reproduction and/or viability. Also provided herein are methods for treating or preventing disease in an insect caused by a pathogen or by external factors (e.g., pollution, environment, stress, weather, etc.). | 2012-12-13 |
20120316221 | COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA - Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-α, airway hyperresponsiveness, and/or pulmonary inflammation. | 2012-12-13 |
20120316222 | NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION - Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that target human cyclophilin A (CyPA) to inhibit Hepatitis C (HCV) infection. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided. | 2012-12-13 |
20120316223 | MODULATION OF pre-mRNA USING SPLICE MODULATING OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS IN THE TREATMENT OF DISEASE - The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity. | 2012-12-13 |
20120316224 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF - Described herein are nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties. Also described herein are methods of making and using nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties. | 2012-12-13 |
20120316225 | Modified INSM1-Promoter for Neuroendocrine Tumor Therapy and Diagnostics - A modification of the existing INSM1 promoter region has been discovered that incorporated DNA elements that silence expression of neuronal genes in non-neuronal cells and that has increased the effectiveness and safety of using the INSM1 promoter for tumor treatment. One modification was addition of one or two tandem copies of neuronal restrictive silencer elements (NRSEs) derived either from the mouse nicotinic acetylcholine receptor (nAChR) or the rat superior cervical ganglion 10 (SCG10) promoters. These NRSEs were placed in the expression construct either directly upstream or downstream of the INSM1 promoter sequence. The most effective expression construct was the nAChR NRSE element positioned downstream of the INSM1 promoter. This expression construct increased the tissue specificity of the INSM1 promoter without a significant decrease in its activity. In addition, the modified INSM1 promoter was placed into a viral vector, adenovirus 5. Constructs with an insulator element, the chicken HS4 β-globin insulator element, with the INSM1 promoter was shown to decrease the interference of the viral genome on its expression. Constructs have been made that do not decrease the INSM1 promoter activity but significantly augment the tumor specificity of the promoter. Linking the construct to a reporter gene allowed for detection of the placement of the viral vector, and this detection can be used for diagnosing or locating neuroendocrine tumors. | 2012-12-13 |
20120316226 | METHODS OF GENE THERAPY FOR TREATING DISORDERS OF THE EAR BY ADMINISTERING A VECTOR ENCODING AN ATONAL-ASSOCIATED FACTOR - The invention is directed to a method of changing the sensory perception of an animal. The method comprises administering an expression vector comprising a nucleic acid sequence encoding an atonal-associated factor, which is expressed to produce the atonal-associated factor resulting in generation of hair cells that allow perception of stimuli in the inner ear. Also provided is a method of generating a hair cell in differentiated sensory epithelia in vivo. The method comprises contacting differentiated sensory epithelial cells with an adenoviral vector (a) deficient in one or more replication-essential gene functions of the E1 region and E4 region, (b) comprising a spacer in the E4 region, and (c) comprising a nucleic acid sequence encoding an atonal-associated factor. The nucleic acid sequence is expressed to produce the atonal-associated factor such that a hair cell is generated. An adenoviral vector encoding an atonal-associated factor also is provided. | 2012-12-13 |
20120316227 | CHRYSOPHAENTIN ANTIMICROBIAL COMPOUNDS THAT INHIBIT FTSZ PROTEIN - Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, and methods for using the chrysophaentin compounds are disclosed. Some embodiments of the disclosed compounds are isolated from | 2012-12-13 |
20120316228 | ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon. | 2012-12-13 |
20120316229 | ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon. | 2012-12-13 |
20120316230 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds of formula (I), where R | 2012-12-13 |
20120316231 | RODENTICIDAL COMPOUNDS, COMPOSITION INCLUDING SAME AND USE THEREOF FOR CONTROLLING HARMFUL RODENTS - A rodenticidal compound of formula (I): as well as the isomers thereof, in particular enantiomers, diastereoisomers, tautomers or mixtures of isomers in all proportions, where: R1 is: H or (II) or (III) with X═H, OH, Cl, Br, F or N0 | 2012-12-13 |
20120316232 | COMBINATION OF A CENTRALLY-ACTING ANALGESIC AND A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR ANTI-INFLAMMATORY AGENT FOR THE TREATMENT OF INFLAMMATION AND PAIN IN THE VETERINARY FIELD - The present invention relates to veterinary pharmaceutical compositions for the treatment of pain and inflammation, containing a combination of Tramadol and Firocoxib, for oral administration. | 2012-12-13 |
20120316233 | Crystalline Solids of a METAP-2 Inhibitor and Methods of Making and Using Same - The disclosure is in part directed to crystalline forms of 6-O-(4- dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof. | 2012-12-13 |
20120316234 | ANTHRAQUINONE -BASED COMPOUND, THE SYNTHESIS PROCESSES AND THE APPLICATION THEREOF - The present invention is related to an anthraquinone-based compound represented by compound (I) | 2012-12-13 |
20120316235 | MATING DISRUPTION METHOD USING ACETATE-CONTAINING MATING DISRUPTANT - Provided is a mating disruption method capable of bringing a stable and effective mating disruption result. Specifically provided is a mating disruption method comprising a step of starting to apply a mating disruptant after mating and oviposition of imagoes of the first generation of an insect pest are substantially over and before imagoes of the second generation of the insect pest emerge, the mating disruptant targeting at least one kind of insect pest which contains one or more kinds of acetates as a natural sex pheromone. | 2012-12-13 |
20120316236 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF - A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: | 2012-12-13 |
20120316237 | Pest Control Composition - It is an object of the present invention to provide a pest control composition capable of exerting a high effect on pests such as spider mites and aphids even at low concentration using a food/food additive with high safety to the human body and the environment. The present inventors have intensively studied to solve the above problem and found that, among polyglycerol fatty acid esters widely used as a food additive, a composition containing a polyglycerol fatty acid ester which has an HLB of 5 or less and is liquid at ordinary temperature and also a nonionic surfactant has a high effect on pests even at low concentration, and that the possibility for pests to develop resistance to the composition is extremely low, and the present invention has been completed. | 2012-12-13 |
20120316238 | NOVEL POLYMOMORPH OF DESVENLAFAXINE BENZOATE - The present invention relates to a novel crystalline form L of (±)-desvenlafaxine benzoate and process for the preparing of the same. Further, the present invention also relates to pharmaceutical composition of novel crystalline form L of desvenlafaxine benzoate and one or more pharmaceutically acceptable excipient. | 2012-12-13 |
20120316239 | METHOD FOR PREPARING PERSONAL CARE COMPOSITION COMPRISING MONOALKYL AMINE DUAL SURFACTANT SYSTEM AND SOLUBLE SALT - Disclosed is a method of preparing a personal care composition wherein the composition comprising a dual cationic surfactant system of a mono-alkyl amine salt and di-alkyl cationic surfactant, high melting point fatty compounds and soluble salts, and wherein the method comprising the following steps: preparing oil phase at a higher temperature; preparing an aqueous phase at a lower temperature; and mixing them in a high shear field with a rotating member. By the addition of a soluble salt, the surfactants, together with high melting point fatty compounds, can effectively transform to emulsions. | 2012-12-13 |
20120316240 | METHOD OF DIAGNOSIS - Disclosed herein are methods that generally to the fields of pharmaceutical chemistry, biochemistry, molecular biology and medicine. More particularly, aspects of the invention concern methods to identify a predisposition for fibrosis in a biological sample, methods of identifying agents that modulate the onset of fibrosis, methods of making a formulation that inhibits the onset or progression of fibrosis, and methods of monitoring the progression of fibrosis or the efficacy of a fibrosis treatment. | 2012-12-13 |
20120316241 | REMEDY FOR CARTILAGE-RELATED DISEASES - The present invention relates an agent for treating cartilage-related disease comprising as an active ingredient a substance having an EP2 and/or EP3 agonist activity. A substance having an agonist activity to EP2 and/or EP3 has effects of stimulating chondrogenesis, stimulating chondrocyte growth, stimulating chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of stimulating integrin mRNA expression, stimulating fibronectin mRNA expression, stimulating D1 mRNA expression and inhibiting osteopontin mRNA expression, and, therefore, is useful as an agent for treating cartilage-related disease. | 2012-12-13 |
20120316242 | METHODS OF TREATING METABOLIC DISORDERS - A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) β/δ of the cells. | 2012-12-13 |
20120316243 | ENHANCED BIMATOPROST OPHTHALMIC SOLUTION - A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein. | 2012-12-13 |
20120316244 | Pharmaceutical Formulations of Modafinil - Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants. | 2012-12-13 |
20120316245 | CO-CRYSTALS OF AGOMELATINE, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - New co-crystal of agomelatine composed of:
| 2012-12-13 |
20120316246 | TOPICAL VASOCONSTRICTOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY - Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided. | 2012-12-13 |
20120316247 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) - Disclosed herein is a method for administering compositions. Also disclosed are kits comprising a compound of formula (I) to (V), or an enantiomer, an analog, a derivative, an isomer, prodrug, or a pharmaceutically acceptable salt thereof, for use in temporal proximity to anesthesia. The methods, compositions and kits provided herein can be used for reducing anesthesia-induced neurotoxicity and post-operative cognitive dysfunction (POCD) in a subject. | 2012-12-13 |
20120316248 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC INFECTIONS - Compositions for treating parasitic infections and methods of using the compositions to treat subjects with parasitic infections are provided. Methods of selecting compositions for use in treating parasitic infections are further provided. | 2012-12-13 |
20120316249 | LYCOPENE FOR THE TREATMENT FOR METABOLIC DYSFUNCTION - This invention relates to the treatment of metabolic dysfunction and disorders associated with metabolic dysfunction using lycopene compounds. Methods of treatment and uses of lycopene compounds in such methods are provided. | 2012-12-13 |
20120316250 | HARD CAPSULE AND METHOD FOR PRODUCING SAME - This invention provides a hard capsule that has excellent stability even when filled with a solvent for dissolving poorly soluble drugs, and that also achieves reduction in disintegration time, thereby ensuring excellent solubility. | 2012-12-13 |
20120316251 | PROCESS FOR PRODUCING COMPOSITIONS FOR USE IN REMOVAL OF DISPERSED, SOLUBILIZED, AND/OR EMULSIFIED UNDESIRED SPECIES FROM WATER AND GASES - Disclosed is a method of making coagulant and viscoelastic compositions for use in removal of dispersed, solubilized, and emulsified oils and hydrocarbons and other noxious species from water and air. The composition comprises thermal reaction products of blends of fatty acids derived, isolated and purified from drying and semi-drying oils such as linseed, safflower, and tung oil with a polymer such as for example poly(isobutyl methacrylate) and can include a solvent. The product of the invention facilitates cohesion of oils and hydrocarbons independent of agitation and temperature and may be used in both salt and fresh water, air and other gaseous streams. | 2012-12-13 |
20120316252 | METHOD FOR PRODUCING SYNTHESIS GAS - It is avoided that the sulfur compounds originating from the castable is mixed into produced synthesis gas, the mixed sulfur compounds are separated and collected with carbon dioxide, the collected carbon dioxide is recycled as raw material gas and then the sulfur compounds is directly supplied to the reformer to consequently degrade the reforming catalyst in the reformer by sulfur poisoning. The carbon dioxide separated and collected in the carbon dioxide removal step is introduced into the desulfurization apparatus of the desulfurization step or the sulfur compounds adsorption apparatus before being recycled to the reformer to remove the sulfur compounds. | 2012-12-13 |
20120316253 | CURABLE COMPOSITION - Disclosed is a curable composition including an organic polymer containing a crosslinkable silyl group, an ultraviolet ray absorbing agent having a triazine skeleton and a hindered amine based light stabilizer. The composition exhibits improved weather resistance in a thin layer and thick layer portion. Further, disclosed is a curable composition including an organic polymer containing a crosslinkable silyl group, a (meth)acrylic polymer containing an epoxy group, a divalent tin organic carboxylate and an organic amine compound. The composition exhibits excellent properties. Also, disclosed is a curable composition and sealing material including a reactive organic polymer containing at least one crosslinkable silyl group in one molecule thereof, a reactive organic polymer containing less than one crosslinkable silyl group in one molecule thereof, and thermally expandable hollow spheres. The composition has good physical properties. Also, disclosed is a fire-resistant structure forming method. | 2012-12-13 |
20120316254 | COMPOSITE MEMORY FOAM AND USES THEREOF - The invention relates to composite memory foam and its uses in the manufacture of mattresses, pillows and other body supports. The invention also relates to a method of manufacturing mattresses, pillows and other body support from composite memory foam. The composite memory foam includes a polyurethane foam and granules of a polyurethane polymer embedded in the polyurethane foam. | 2012-12-13 |
20120316255 | STRENGTH-IMPROVING AGENT FOR PRODUCTION OF POLYURETHANE FOAM - Provided is a strength-improving agent for the production of polyurethane foam, said agent enabling the production of a polyurethane foam having high tensile strength, tear strength and compressive strength. A strength-improving agent (A) for the production of polyurethane foam, represented by general formula (I) [wherein each R1 is a residue derived from an active-hydrogen containing compound by the removal of one active hydrogen atom, and multiple R1s may be the same or different; Y is a residue derived from an at least trivalent aromatic polycarboxylic acid (C) by the removal of the carboxyl groups; the aromatic ring of Y is composed of carbon atoms; the substituents on the aromatic ring maybe hydrogen or other groups, with the proviso that at least one of the substituents is hydrogen; a is an integer satisfying the relationship: 2≦a≦[(the number of substituents on the aromatic ring)−2]; Z is a residue derived from an at least m-valent active-hydrogen containing compound by the removal of m active hydrogen atoms; some R1s and Z may be the same, with the proviso that at least one R1 is different from Z; and m is an integer of 1 to 10]. | 2012-12-13 |
20120316256 | Polymers for Contact Lenses - The present invention relates to a polyurethane polymer composition comprising polyethyleneglycol dialkyl ether. There is also provided a process for preparing a polyurethane. The invention also relates to a process for preparing a polyurethane xerogel in the form of a molded article, said process comprising the steps of: i. preparing a mixture of a. at least one polyethylene glycol or at least one polyol of formula (I), wherein at least three Of X | 2012-12-13 |
20120316257 | BIODEGRADABLE COMPOSITION COMPRISING POLYMERS OF NATURAL ORIGIN AND ALIPHATIC-AROMATIC COPOLYESTERS - The present invention relates to a biodegradable composition comprising at least one polymer of natural origin and at least one aliphatic-aromatic copolyester obtained starting from mixtures comprising aliphatic diols, polyfunctional aromatic acids, and at least two aliphatic dicarboxylic acids, at least one of which is long chain. Said composition combines improved biodegradability, excellent mechanical properties, a high level of industrial processability, limited environmental impact as well as stability of physical properties under the influence of environmental factors. | 2012-12-13 |
20120316258 | Rubber Clay for Handicrafts - Disclosed is rubber clay for handicrafts. The rubber clay does not stick to the hands because it is manufactured by using a non-stick, inorganic compound having excellent transparency as the main component, the rubber clay is reusable because it does not harden even when a structure (model) made of the rubber clay is left for a long time, and the rubber clay may be represented in a wide range of colors. To this end, the rubber clay for handicrafts according to the present invention contains 60 to 80% by weight of a gel-type silicone base, 15 to 35% by weight of a plasticity adjuster, 1 to 5% by weight of an oil-type anti-cracking agent, and 0.1 to 1% by weight of an antimicrobial agent. | 2012-12-13 |